Incannex Healthcare Limited - Utang jangka cendhak perusahaan IXHL

Incannex Healthcare (IXHL) aims to become a pioneer in psychedelic and cannabinoid therapies, leveraging rigorous scientific research. The company is currently deploying its available capital toward costly clinical trials for new drugs. Future revenues are projected to stem from the treatment of sleep apnea and brain injuries. The volume of short-term loans illustrates borrowing dynamics, where 0.00 reflects the baseline level of the metric.

This metric measures the total liabilities due within twelve months, determining the company's liquidity and default risk. Analyzing financial obligations with a maturity of up to one year allows for an assessment of Incannex Healthcare (IXHL) stability during the period of adapting its clinical platform to US standards and management's focus on completing trials for smokeless pharmaceutical products.